Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up

Knappe, Luisa; Giovanella, Luca

doi:10.1080/17446651.2021.1993060

Cited by 17 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study results showed that the HMGB-1 and SIL-2R levels among the thyroid cancer group, benign lesion group and control group were significantly different ( P < 0.001). TgAb is a soluble iodinated glycoprotein synthesized and secreted by thyroid epithelial cells that is able to exert mutual effect with binding antibodies via Fc receptors to activate NK cells and then attack target cells, causing destruction of thyroid cells [ 23 ]. Scholars Kang et al stated that TgAb can serve as an important factor in predicting thyroid cancer, and its diagnostic efficacy in combination with ultrasound is superior to that of a single test [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer

Zhang

Meng

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. The aim of this study is to explore the clinical application value of high-frequency ultrasound combined with detection of serum high mobility group box (HMGB-1), soluble IL-2 receptor (SIL-2R), and thyroglobulin antibody (TgAb) in diagnosing thyroid cancer. Methods. By means of retrospective study, 50 thyroid cancer patients treated in our hospital from January 2019 to January 2021 were selected as the thyroid cancer group, 50 patients with benign thyroid lesions were included in the benign lesion group, and 50 healthy individuals examined in our hospital in the same period were included in the control group. All study objects received high-frequency ultrasound examination, and at the same time, their serum HMGB-1, SIL-2R, and TgAb levels were measured. After that, the results of high-frequency ultrasound examination were analyzed, the diagnostic efficacy of different diagnosis methods was explored, and receiver operating characteristic (ROC) curves were plotted. Results. According to the results of high-frequency ultrasound examination, there were significant differences in echogenicity surrounding and inside the lesion, calcification, blood flow distribution, and blood flow parameters between the thyroid cancer group and the benign lesion group (P < 0.001); the HMGB-1, SIL-2R, and TgAb levels were statistically different among the three groups (P < 0.001), and the level values of HMGB-1, SIL-2R, and TgAb of the thyroid cancer group were, respectively, (12.26 ± 1.32) ng/ml, (108.65 ± 9.75) pmol/L, and (690.65 ± 34.47) IU/mL; the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of high-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb were, respectively, 98.0%, 95.0%, 90.7%, and 99.0%, and AUC (95%CI) = 0.965 (0.931–0.999). Conclusion. High-frequency ultrasound combined with detection of serum HMGB-1, SIL-2R, and TgAb has a good value in diagnosing thyroid cancer, which should be promoted in practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer

Zhang

Meng

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Serum Tg can be secreted by normal thyroid follicular epithelial cells or well-differentiated DTC cells and is affected by postoperative residual thyroid tissue, serum TSH, and TgAb levels. Previous studies have shown that changes in serum psTg levels are an important factor in disease remission, persistence, recurrence, and prognosis after DTC treatment and are an important indicator in efficacy evaluations, disease monitoring, and determining prognoses in long-term follow-up (11)(12)(13). In this study, multivariate analysis indicated that psTg was an independent factor for predicting ER (OR: 1.325; 95% CI: 1.135-1.547; P<0.001), which was consistent with previous research by Webb et al in a meta-analysis of more than 4,000 cases of DTC (14).…”

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Zhao¹,

Han²,

Lu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background 131 I treatment is one of the important methods of comprehensive postoperative treatment for patients with hyperthyroidism complicated with differentiated thyroid cancer (DTC). Early identification of patients with poor treatment efficacy of 131 I is particularly important. Current studies mainly focus on the relationship between hyperthyroidism and the occurrence and development of DTC, and there are few studies on the factors affecting the curative effect. The purpose of this study was to find the influencing factors of efficacy evaluation and provide evidence for early identification of patients with poor efficacy in DTC combined with primary hyperthyroidism patients. Methods This was a retrospective analysis of DTC patients with primary hyperthyroidism who received 131 I treatment in our department from 2012 to 2021. Follow-up intervals were 3 months within 1 year, 6 months within 1 to 2 years, and annual follow-up thereafter, the median follow-up time was 12.0 (3.0, 24.0) months. Serological examination and imaging examination were used to evaluate the efficacy. Patients were classified into an excellent response (ER) group and a non-ER group based on treatment response more than 6 months after 131 I treatment. Univariate analysis and multivariate logistic regression analysis were performed on the basic clinical characteristics, pathological characteristics and curative effect of the patients, in order to find independent risk factors affecting the curative effect. Results Eighty-nine patients were mostly female (80.9%), the average age was 43.47±11.88 years old, and tumor size was 1.2 (0.75, 1.80) cm, 56 patients (62.9%) in the ER group. psTg [odds ratio (OR): 1.325; 95% confidence interval (CI): 1.135–1.547; P<0.001], maximum tumor diameter (OR: 2.428; 95% CI: 1.392–4.235; P=0.002) and pathology-confirmed combined HT (OR: 8.669; 95% CI: 1.877–40.038; P=0.006) were independent risk factors for predicting ER. Conclusions Our findings demonstrate that most hyperthyroidism combined with DTC patients could get favorable clinical outcomes from 131 I treatment. The tumor diameter, pathology-confirmed diagnosis of combined HT, and psTg level can be used to identify patients who can get ER by the effect of 131 I in hyperthyroidism combined with DTC at an early stage.

show abstract

“…Thyroglobulin measurement and ultrasound are essential tools to monitor DTC after primary treatment [ 5 , 24 , 45 , 46 ].…”

Section: Differentiated Thyroid Cancersmentioning

confidence: 99%

Molecular Imaging and Theragnostics of Thyroid Cancers

Giovanella

Deandreis

Vrachims³

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Molecular imaging plays an important role in the evaluation and management of different thyroid cancer histotypes. The existing risk stratification models can be refined, by incorporation of tumor-specific molecular markers that have theranostic power, to optimize patient-specific (individualized) treatment decisions. Molecular imaging with varying radioisotopes of iodine (i.e., 131I, 123I, 124I) is an indispensable component of dynamic and theragnostic risk stratification of differentiated carcinoma (DTC) while [18F]F-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) helps in addressing disease aggressiveness, detects distant metastases, and risk-stratifies patients with radioiodine-refractory DTC, poorly differentiated and anaplastic thyroid cancers. For medullary thyroid cancer (MTC), a neuroendocrine tumor derived from thyroid C-cells, [18F]F-dihydroxyphenylalanine (6-[18F]FDOPA) PET/CT and/or [18F]FDG PET/CT can be used dependent on serum markers levels and kinetics. In addition to radioiodine therapy for DTC, some theragnostic approaches are promising for metastatic MTC as well. Moreover, new redifferentiation strategies are now available to restore uptake in radioiodine-refractory DTC while new theragnostic approaches showed promising preliminary results for advanced and aggressive forms of follicular-cell derived thyroid cancers (i.e., peptide receptor radiotherapy). In order to help clinicians put the role of molecular imaging into perspective, the appropriate role and emerging opportunities for molecular imaging and theragnostics in thyroid cancer are discussed in our present review.

show abstract

Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up

Cited by 17 publications

References 15 publications

Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer

Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Molecular Imaging and Theragnostics of Thyroid Cancers

Contact Info

Product

Resources

About